List of Excipients in Branded Drug RUGBY NICOTINE POLACRILEX GUM, COATED FRUIT FLAVOR

« Back to Dashboard

Generic Drugs Containing RUGBY NICOTINE POLACRILEX GUM, COATED FRUIT FLAVOR

Company	Ingredient	NDC	Excipient
Rugby Laboratories	nicotine polacrilex	0536-3386	ACACIA
Rugby Laboratories	nicotine polacrilex	0536-3386	ACESULFAME POTASSIUM
Rugby Laboratories	nicotine polacrilex	0536-3386	CARNAUBA WAX
Rugby Laboratories	nicotine polacrilex	0536-3386	FD&C BLUE NO. 2 ALUMINUM LAKE
Rugby Laboratories	nicotine polacrilex	0536-3386	FD&C RED NO. 40 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in RUGBY NICOTINE POLACRILEX GUM, COATED FRUIT FLAVOR?

# Of NDCs	Excipient
1	ACACIA
1	ACESULFAME POTASSIUM
1	CARNAUBA WAX
1	FD&C BLUE NO. 2 ALUMINUM LAKE
1	FD&C RED NO. 40 ALUMINUM LAKE

Rugby Nicotine Polacrilex Gum, Coated Fruit Flavor: Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Rugby Nicotine Polacrilex Gum, Coated Fruit Flavor is an OTC nicotine-replacement product whose commercial value depends more on taste, chew mechanics, nicotine-release performance, packaging, and retail execution than on patent exclusivity. The principal opportunities are improved palatability, reduced mouth irritation, stronger moisture protection, better adherence to quit-smoking regimens, and differentiated private-label distribution.

What is Rugby Nicotine Polacrilex Gum, Coated Fruit Flavor?

Rugby nicotine polacrilex gum is an oral nicotine-replacement therapy supplied in coated chewing-gum units. Nicotine polacrilex is a resin complex that releases nicotine during chewing and mixing with saliva. The product is intended to reduce nicotine withdrawal symptoms associated with smoking cessation.

Public product listings identify Rugby fruit-flavor gum in conventional 2-mg and 4-mg nicotine strengths. The product is generally marketed for adults who smoke cigarettes and is labeled for use under an OTC smoking-cessation regimen. The exact strength, package count, manufacturer, and inactive-ingredient statement should be determined from the applicable National Drug Code and current package label.

Product attribute	Commercial relevance
Active ingredient	Nicotine polacrilex
Common strengths	2 mg and 4 mg nicotine per gum unit
Dosage form	Medicated chewing gum
Flavor	Coated fruit flavor
Regulatory category	OTC nicotine-replacement therapy
Primary channel	Retail pharmacy, mass retail, e-commerce, institutional and private-label channels
Core value driver	Taste and adherence rather than molecular innovation
Patent position	Mature, low-barrier active ingredient and dosage form
Key technical risks	Nicotine release, taste persistence, mouth irritation, moisture uptake and packaging stability

What excipients are used in nicotine polacrilex gum?

Nicotine gum requires excipients that control chew texture, saliva-triggered nicotine release, sweetness, flavor intensity, coating integrity, and moisture stability. The formulation normally combines a gum base with polyols, alkaline release modifiers, flavoring agents, coating materials, lubricants, and high-intensity sweeteners.

Public labeling for nicotine polacrilex gum products commonly identifies excipient classes such as:

• Gum base
• Sorbitol and other polyols
• Sodium carbonate or related alkalizing agents
• Flavoring agents
• Humectants such as glycerin
• High-intensity sweeteners
• Talc or other processing aids
• Coating polymers and opacifying agents

The exact Rugby formulation should be read from the current DailyMed label and package insert. Formulation details may vary by strength, flavor, supplier, and manufacturing site. DailyMed is the principal public source for the product’s current inactive-ingredient declaration and labeling history.[1]

Functional role of the major excipient classes

Excipient class	Technical function	Commercial consequence
Gum base	Provides chew structure and controls mastication	Determines mouthfeel, chew duration and release profile
Polyols	Provide bulk sweetness and reduce reliance on sucrose	Supports sugar-free positioning
Alkalizing agents	Increase nicotine release from the resin complex by raising local pH	Affects onset, throat sensation and irritation
Flavor systems	Mask nicotine bitterness and alkaline taste	Strongly affects repeat use and adherence
Humectants	Manage flexibility and prevent excessive brittleness	Influences shelf life and chew quality
Coating polymers	Protect the gum surface and deliver initial flavor	Supports appearance, handling and taste onset
High-intensity sweeteners	Add sweetness at low use levels	Enables lower-calorie, sugar-free products
Processing aids	Improve compression, coating and manufacturing flow	Reduce rejects and improve batch consistency

How does the excipient strategy affect nicotine release?

The release mechanism is controlled by the interaction between chewing, saliva, gum-base structure, resin particle distribution, and local pH. Alkaline excipients help liberate free nicotine from nicotine polacrilex. Excess alkalinity can increase throat burn, mouth irritation and unpleasant aftertaste.

A commercially effective formulation must balance four variables:

1. Sufficient nicotine release during the recommended chew-and-park method.
2. A manageable initial flavor burst.
3. Limited bitterness and alkaline irritation.
4. A chew texture that remains acceptable during extended use.

A product that releases nicotine too slowly can reduce perceived efficacy. A product that releases nicotine too rapidly can increase irritation and discourage continued use. This makes excipient optimization a product-performance issue rather than a cosmetic exercise.

What formulation changes offer the greatest value?

The strongest near-term opportunities are:

• More durable fruit flavor after the initial coating dissolves.
• Lower nicotine bitterness through layered flavor systems.
• Reduced throat burn through controlled alkalinity.
• Better chew softness over the full labeled shelf life.
• More consistent release across individual gum units.
• Reduced tackiness at elevated temperature and humidity.
• Better mouthfeel for users who dislike conventional nicotine gum.

Flavor design should use a staged profile. The coating can provide rapid fruit flavor on placement, while the gum matrix can deliver a lower-intensity background flavor during chewing. A single strong flavor burst may improve first-use impressions but can create an unpleasant transition when nicotine release increases.

What formulation patents protect nicotine polacrilex gum?

The commercial patent barrier for nicotine gum is weak compared with newer drug-delivery systems. Nicotine replacement products have been marketed for decades, and the basic concepts of nicotine polacrilex, medicated gum, alkaline release modification, and fruit flavoring are mature technologies.

The main protection opportunities are likely to involve:

• Specific excipient ratios.
• Coating architecture.
• Dual-phase flavor delivery.
• Particle-size control for nicotine polacrilex.
• Moisture-barrier packaging.
• Release profiles that reduce irritation.
• Combination products involving nicotine gum and other nicotine-delivery forms.
• Manufacturing processes that improve content uniformity or stability.

A new formulation patent would need meaningful technical differentiation. A generic claim covering nicotine gum, fruit flavor, sorbitol, gum base, and an alkalizing agent would face substantial validity and obviousness risk because these elements are well established in the field.

How strong is the patent estate for Rugby nicotine gum?

The estate is best characterized as low-strength from a blocking perspective and potentially moderate-strength for narrowly drafted formulation or manufacturing claims. The product’s commercial defense is more likely to come from:

• Brand recognition.
• Retail distribution.
• Private-label contracts.
• Manufacturing scale.
• Taste acceptance.
• Packaging and compliance execution.
• Regulatory familiarity.

No current product-specific composition patent or Orange Book-listed patent is generally associated with the Rugby OTC nicotine-gum product. OTC monograph status reduces the relevance of Orange Book patent disputes compared with prescription drugs.[2]

What is the FDA regulatory status of Rugby nicotine gum?

Nicotine-replacement products are regulated as OTC smoking-cessation products under the FDA’s regulatory framework for nicotine products intended to help adults stop smoking. The relevant framework includes FDA OTC drug regulations and the labeling requirements for nicotine gum and related nicotine-replacement products.[3]

The regulatory strategy is based on conformity with:

• Active-ingredient requirements.
• Strength and dosage-form requirements.
• Directions for use.
• Warnings and contraindications.
• Drug Facts labeling.
• Manufacturing controls under current good manufacturing practice.
• Stability and quality specifications.
• Packaging requirements, including child-resistant considerations where applicable.

A materially reformulated product may require a regulatory assessment even if it remains within the OTC framework. Changes to nicotine release, dosage-unit composition, labeling, claims, or delivery performance can affect the regulatory pathway.

What is the Orange Book status of Rugby nicotine polacrilex gum?

Rugby nicotine gum is generally treated as an OTC monograph product rather than an NDA product with a conventional Orange Book patent listing. That distinction reduces the likelihood of a traditional Paragraph IV litigation pathway.

Issue	Rugby nicotine gum implication
Orange Book patent listing	Not generally the principal exclusivity mechanism
NDA exclusivity	Not the primary commercial protection
Paragraph IV challenge	Usually not the central entry route for an OTC monograph product
Regulatory entry	OTC monograph compliance and applicable FDA requirements
Commercial defense	Brand, distribution, formulation quality and manufacturing economics

When does Rugby nicotine gum lose exclusivity?

Rugby nicotine gum does not have a conventional prescription-drug exclusivity date comparable to a new molecular entity or a newly approved NDA. The active ingredient and dosage form are mature. Market entry is therefore constrained mainly by regulatory compliance, manufacturing capability, product quality, retailer access and consumer demand.

What generic entry risks exist?

Generic and private-label entry risk is high because:

• Nicotine is an established active ingredient.
• Nicotine gum is a mature dosage form.
• The formulation uses widely available excipient classes.
• The product is sold in an OTC market with multiple established competitors.
• Switching costs for retailers and consumers are limited.
• Formulation differentiation can be difficult to communicate at shelf.

The key barrier is not patent infringement. It is execution. A new entrant must match nicotine release, taste, texture, stability, labeling and retail economics.

Which companies compete with Rugby nicotine gum?

The competitive landscape includes branded and store-brand nicotine gum products from major consumer-health companies, generic drug manufacturers, pharmacy chains and online retailers. Major competitive reference products include Nicorette nicotine gum and private-label equivalents sold through pharmacy and mass-retail channels.[4]

Competitor type	Competitive advantage
Branded nicotine gum	Consumer recognition and clinical familiarity
Store-brand gum	Lower price and retailer control
Generic pharmaceutical manufacturer	Manufacturing efficiency and broad distribution
E-commerce brand	Direct consumer acquisition and assortment flexibility
Combination-NRT seller	Ability to cross-sell patches, lozenges and gum

Rugby’s likely advantage is channel access through pharmaceutical distribution and private-label procurement. Its vulnerability is limited consumer differentiation if the product is perceived as interchangeable with lower-priced alternatives.

What commercial opportunities exist for excipient innovation?

Premium fruit-flavor positioning

Fruit flavor can support a premium or differentiated product if it provides a more acceptable alternative to mint. The formulation should avoid excessive sweetness, artificial flavor persistence and flavor-nicotine conflict.

Potential extensions include:

• Berry.
• Citrus.
• Tropical fruit.
• Mixed fruit.
• Mild fruit-mint combinations.
• Seasonal or limited-edition flavors.

Flavor diversification may expand use among consumers who do not tolerate traditional mint products, but each new flavor requires stability, sensory and label review.

Low-irritation nicotine gum

A lower-irritation product could target consumers who discontinue nicotine gum because of burning, hiccups, nausea or throat discomfort. The development program would focus on:

• Alkalizer concentration.
• Nicotine-particle distribution.
• Gum-base release properties.
• Flavor masking.
• Chew duration.
• Saliva interaction.

The commercial claim must remain within permissible OTC labeling. Marketing language that implies superior cessation efficacy would require appropriate substantiation and regulatory review.

Improved packaging

Packaging is a high-value, lower-risk development area. Nicotine gum is sensitive to moisture, heat and flavor migration. Opportunities include:

• High-barrier blister packaging.
• Unit-dose foil structures.
• Resealable bottles with improved desiccant control.
• Child-resistant formats.
• Calendar packs that support adherence.
• Compact travel packs.
• Tamper-evident packaging.

Packaging improvements can create practical differentiation without changing the active ingredient or core gum matrix.

Combination nicotine-replacement systems

Rugby or a manufacturing partner could package nicotine gum with nicotine patches or lozenges. Combination-NRT kits may increase basket size and support a complete cessation regimen. The primary commercial risks are labeling complexity, inventory management and the need to avoid dosing confusion.

Institutional and public-health supply

Large-volume opportunities include employer wellness programs, Medicaid and public-health smoking-cessation initiatives, correctional healthcare, military procurement and pharmacy adherence programs. These channels prioritize:

• Unit cost.
• Shelf stability.
• Consistent supply.
• Clear dosing instructions.
• Broad strength availability.
• Documentation of quality systems.

What manufacturing and intellectual-property barriers matter?

The active ingredient is not the primary barrier. Manufacturing barriers include:

• Uniform dispersion of nicotine polacrilex.
• Control of gum-base rheology.
• Coating adhesion.
• Flavor uniformity.
• Moisture control.
• Content uniformity.
• Release testing.
• Stability under temperature cycling.
• Packaging-line compatibility.

A contract manufacturer with established medicated-gum capability can reduce development time. The most valuable manufacturing know-how may be protected as trade secrets rather than patents, particularly in mixing order, temperature control, coating parameters, resin dispersion and packaging conditions.

Geographic coverage is also commercially relevant. A U.S. OTC product may require separate assessments for Canada, the European Union, the United Kingdom, Australia and other markets. Nicotine-replacement labeling, permitted excipients, child-resistant packaging and product authorization pathways differ by jurisdiction.

What litigation and settlement risks affect Rugby nicotine gum?

No major Paragraph IV litigation or settlement structure is normally associated with this type of OTC nicotine-gum product. The more relevant disputes would concern:

• Trademark and trade dress.
• Contract manufacturing.
• Retailer exclusivity.
• Product-quality claims.
• Labeling and advertising.
• Consumer injury allegations.
• Supply agreements.
• Distribution territories.

The absence of a conventional patent litigation pathway increases the importance of commercial contracting and quality compliance.

How does Rugby compare with branded Nicorette gum?

Factor	Rugby nicotine gum	Nicorette nicotine gum
Positioning	Generic, private-label or value channel	Branded consumer-health product
Patent dependence	Low	Low for core mature product
Consumer recognition	Usually lower	Usually higher
Price leverage	Stronger in value channels	Stronger where brand matters
Flavor opportunity	High if private-label reformulation is permitted	Constrained by brand architecture but supported by marketing
Retail strategy	Distributor and retailer relationships	Brand-led shelf placement and advertising
Main moat	Cost, supply and channel access	Brand, awareness and consumer trust

What revenue exposure and investment factors matter?

Product-specific revenue cannot be inferred from the product name alone. The most important commercial metrics are:

• Annual unit volume.
• Gross margin per gum unit.
• Retailer and distributor deductions.
• Share by nicotine strength.
• Repeat purchase rate.
• Flavor-level sales mix.
• Returns and quality complaints.
• Manufacturing yield.
• Packaging cost per treatment day.
• Contract renewal rates.
• E-commerce conversion and repeat ordering.

The highest-value investment case is a scalable platform rather than a single flavor. A manufacturer that can transfer the same gum matrix across fruit, mint, cinnamon and unflavored variants can reduce development and validation costs.

Key Takeaways

• Rugby nicotine polacrilex gum is a mature OTC nicotine-replacement product with limited core patent protection.
• Excipient selection controls taste, chew texture, nicotine release, irritation and shelf stability.
• Fruit flavor creates a differentiation opportunity, especially for consumers who dislike mint nicotine gum.
• Packaging, low-irritation release and adherence-oriented formats offer stronger commercial opportunities than basic active-ingredient changes.
• Paragraph IV litigation and Orange Book patent disputes are generally less relevant than OTC compliance, manufacturing quality and retailer access.
• The strongest defensible assets are likely to be formulation know-how, manufacturing processes, packaging systems, contracts and brand or private-label distribution.
• Commercial success depends on repeat use, acceptable mouthfeel, reliable nicotine release and low delivered cost.

FAQs

Is Rugby nicotine gum sugar-free?

Nicotine gum products are generally formulated with polyols and high-intensity sweeteners rather than sucrose. The current Rugby label should be used to confirm the exact sweetener system and any applicable sugar-free claim.

Can a company reformulate Rugby nicotine gum with a new flavor?

A flavor change may be commercially feasible, but it requires review of the inactive-ingredient declaration, stability, sensory performance, nicotine-release profile, manufacturing process and labeling.

Does nicotine gum require a Paragraph IV certification?

A conventional Paragraph IV certification is generally associated with an abbreviated application referencing a patent-listed prescription drug. OTC monograph nicotine gum is not ordinarily dependent on that pathway.

What is the most valuable excipient innovation for nicotine gum?

A low-irritation, staged-release flavor system is among the strongest opportunities because it addresses taste, mouthfeel, nicotine release and adherence in a single product-development program.

Can fruit-flavor nicotine gum be sold outside the United States?

Potentially, but each jurisdiction applies its own rules for nicotine-replacement products, excipients, claims, packaging, pharmacovigilance and marketing authorization. U.S. OTC compliance does not automatically establish approval in another market.

References

1. National Library of Medicine. (n.d.). DailyMed: Nicotine polacrilex gum product labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Nicotine-containing products and smoking cessation products. FDA.
4. Johnson & Johnson Consumer Inc. (n.d.). Nicorette nicotine gum product information. Nicorette.